Miami-based DOR BioPharma has signed a letter of intent to buy Denmark's Gastrotech Pharma for $9 million in stock. Gastrotech develops therapeutics based on peptide hormones to treat cancer and gastrointestinal diseases. Gastrotech was founded on technology developed at the Sahlgrenska University Hospital in Sweden.
- read this press release for more information